Report Detail

Other Global Active Pharmaceutical Ingredients (API) CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4509850
  • |
  • 13 February, 2023
  • |
  • Global
  • |
  • 111 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

According to our (Global Info Research) latest study, the global Active Pharmaceutical Ingredients (API) CDMO market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Active Pharmaceutical Ingredients (API) CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Active Pharmaceutical Ingredients (API) CDMO market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Active Pharmaceutical Ingredients (API) CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Active Pharmaceutical Ingredients (API) CDMO market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Recipharm, Cambrex Corporation, Patheon (Thermo Fisher Scientific), CordenPharma and Lonza, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Active Pharmaceutical Ingredients (API) CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Macromolecular API
Small Molecule API
Market segment by Application
Clinical
Commercial
Others
Market segment by players, this report covers
Recipharm
Cambrex Corporation
Patheon (Thermo Fisher Scientific)
CordenPharma
Lonza
Siegfried
Catalent
Boehringer Ingelheim
Piramal Group
AbbVie
SGS Quay Pharmaceuticals
Aenova Group
Curia
Sterling Pharma Solutions
Eurofins CDMO
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Active Pharmaceutical Ingredients (API) CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Active Pharmaceutical Ingredients (API) CDMO, with revenue, gross margin and global market share of Active Pharmaceutical Ingredients (API) CDMO from 2018 to 2023.
Chapter 3, the Active Pharmaceutical Ingredients (API) CDMO competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Active Pharmaceutical Ingredients (API) CDMO market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Active Pharmaceutical Ingredients (API) CDMO.
Chapter 13, to describe Active Pharmaceutical Ingredients (API) CDMO research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Active Pharmaceutical Ingredients (API) CDMO
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Active Pharmaceutical Ingredients (API) CDMO by Type
    • 1.3.1 Overview: Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Type in 2022
    • 1.3.3 Macromolecular API
    • 1.3.4 Small Molecule API
  • 1.4 Global Active Pharmaceutical Ingredients (API) CDMO Market by Application
    • 1.4.1 Overview: Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Clinical
    • 1.4.3 Commercial
    • 1.4.4 Others
  • 1.5 Global Active Pharmaceutical Ingredients (API) CDMO Market Size & Forecast
  • 1.6 Global Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast by Region
    • 1.6.1 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Size by Region, (2018-2029)
    • 1.6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
    • 1.6.6 South America Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Active Pharmaceutical Ingredients (API) CDMO Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Recipharm
    • 2.1.1 Recipharm Details
    • 2.1.2 Recipharm Major Business
    • 2.1.3 Recipharm Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.1.4 Recipharm Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Recipharm Recent Developments and Future Plans
  • 2.2 Cambrex Corporation
    • 2.2.1 Cambrex Corporation Details
    • 2.2.2 Cambrex Corporation Major Business
    • 2.2.3 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.2.4 Cambrex Corporation Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Cambrex Corporation Recent Developments and Future Plans
  • 2.3 Patheon (Thermo Fisher Scientific)
    • 2.3.1 Patheon (Thermo Fisher Scientific) Details
    • 2.3.2 Patheon (Thermo Fisher Scientific) Major Business
    • 2.3.3 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.3.4 Patheon (Thermo Fisher Scientific) Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Patheon (Thermo Fisher Scientific) Recent Developments and Future Plans
  • 2.4 CordenPharma
    • 2.4.1 CordenPharma Details
    • 2.4.2 CordenPharma Major Business
    • 2.4.3 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.4.4 CordenPharma Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 CordenPharma Recent Developments and Future Plans
  • 2.5 Lonza
    • 2.5.1 Lonza Details
    • 2.5.2 Lonza Major Business
    • 2.5.3 Lonza Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.5.4 Lonza Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Lonza Recent Developments and Future Plans
  • 2.6 Siegfried
    • 2.6.1 Siegfried Details
    • 2.6.2 Siegfried Major Business
    • 2.6.3 Siegfried Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.6.4 Siegfried Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Siegfried Recent Developments and Future Plans
  • 2.7 Catalent
    • 2.7.1 Catalent Details
    • 2.7.2 Catalent Major Business
    • 2.7.3 Catalent Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.7.4 Catalent Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Catalent Recent Developments and Future Plans
  • 2.8 Boehringer Ingelheim
    • 2.8.1 Boehringer Ingelheim Details
    • 2.8.2 Boehringer Ingelheim Major Business
    • 2.8.3 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.8.4 Boehringer Ingelheim Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Boehringer Ingelheim Recent Developments and Future Plans
  • 2.9 Piramal Group
    • 2.9.1 Piramal Group Details
    • 2.9.2 Piramal Group Major Business
    • 2.9.3 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.9.4 Piramal Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Piramal Group Recent Developments and Future Plans
  • 2.10 AbbVie
    • 2.10.1 AbbVie Details
    • 2.10.2 AbbVie Major Business
    • 2.10.3 AbbVie Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.10.4 AbbVie Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 AbbVie Recent Developments and Future Plans
  • 2.11 SGS Quay Pharmaceuticals
    • 2.11.1 SGS Quay Pharmaceuticals Details
    • 2.11.2 SGS Quay Pharmaceuticals Major Business
    • 2.11.3 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.11.4 SGS Quay Pharmaceuticals Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 SGS Quay Pharmaceuticals Recent Developments and Future Plans
  • 2.12 Aenova Group
    • 2.12.1 Aenova Group Details
    • 2.12.2 Aenova Group Major Business
    • 2.12.3 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.12.4 Aenova Group Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Aenova Group Recent Developments and Future Plans
  • 2.13 Curia
    • 2.13.1 Curia Details
    • 2.13.2 Curia Major Business
    • 2.13.3 Curia Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.13.4 Curia Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Curia Recent Developments and Future Plans
  • 2.14 Sterling Pharma Solutions
    • 2.14.1 Sterling Pharma Solutions Details
    • 2.14.2 Sterling Pharma Solutions Major Business
    • 2.14.3 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.14.4 Sterling Pharma Solutions Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Sterling Pharma Solutions Recent Developments and Future Plans
  • 2.15 Eurofins CDMO
    • 2.15.1 Eurofins CDMO Details
    • 2.15.2 Eurofins CDMO Major Business
    • 2.15.3 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Product and Solutions
    • 2.15.4 Eurofins CDMO Active Pharmaceutical Ingredients (API) CDMO Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Eurofins CDMO Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Active Pharmaceutical Ingredients (API) CDMO Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Active Pharmaceutical Ingredients (API) CDMO by Company Revenue
    • 3.2.2 Top 3 Active Pharmaceutical Ingredients (API) CDMO Players Market Share in 2022
    • 3.2.3 Top 6 Active Pharmaceutical Ingredients (API) CDMO Players Market Share in 2022
  • 3.3 Active Pharmaceutical Ingredients (API) CDMO Market: Overall Company Footprint Analysis
    • 3.3.1 Active Pharmaceutical Ingredients (API) CDMO Market: Region Footprint
    • 3.3.2 Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Type Footprint
    • 3.3.3 Active Pharmaceutical Ingredients (API) CDMO Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Active Pharmaceutical Ingredients (API) CDMO Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Active Pharmaceutical Ingredients (API) CDMO Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
  • 6.2 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
  • 6.3 North America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
    • 6.3.1 North America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
    • 6.3.2 United States Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
  • 7.2 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
  • 7.3 Europe Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
    • 7.3.1 Europe Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 7.3.3 France Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Market Size by Region
    • 8.3.1 Asia-Pacific Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Region (2018-2029)
    • 8.3.2 China Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 8.3.5 India Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
  • 9.2 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
  • 9.3 South America Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
    • 9.3.1 South America Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Market Size by Country
    • 10.3.1 Middle East & Africa Active Pharmaceutical Ingredients (API) CDMO Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Active Pharmaceutical Ingredients (API) CDMO Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Active Pharmaceutical Ingredients (API) CDMO Market Drivers
  • 11.2 Active Pharmaceutical Ingredients (API) CDMO Market Restraints
  • 11.3 Active Pharmaceutical Ingredients (API) CDMO Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Active Pharmaceutical Ingredients (API) CDMO Industry Chain
  • 12.2 Active Pharmaceutical Ingredients (API) CDMO Upstream Analysis
  • 12.3 Active Pharmaceutical Ingredients (API) CDMO Midstream Analysis
  • 12.4 Active Pharmaceutical Ingredients (API) CDMO Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Active Pharmaceutical Ingredients (API) CDMO. Industry analysis & Market Report on Active Pharmaceutical Ingredients (API) CDMO is a syndicated market report, published as Global Active Pharmaceutical Ingredients (API) CDMO Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Active Pharmaceutical Ingredients (API) CDMO market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,738.76
    4,108.14
    5,477.52
    3,205.08
    4,807.62
    6,410.16
    543,610.80
    815,416.20
    1,087,221.60
    289,988.40
    434,982.60
    579,976.80
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report